Literature DB >> 24849088

Bevacizumab for newly diagnosed glioblastoma.

Mark R Gilbert, Erik P Sulman, Minesh P Mehta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24849088     DOI： 10.1056/NEJMc1403303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  39 in total

Review 1.  Antiangiogenic therapy for glioblastoma: current status and future prospects.

Authors:  Tracy T Batchelor; David A Reardon; John F de Groot; Wolfgang Wick; Michael Weller
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

2.  Predicting glioblastoma response to bevacizumab through marker profiling?

Authors:  Tobias Kessler
Journal:  Neuro Oncol       Date:  2016-02       Impact factor: 12.300

3.  The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.

Authors:  Abdel Nasser Hosein; Yi Chieh Lim; Bryan Day; Brett Stringer; Stephen Rose; Richard Head; Leah Cosgrove; Peter Sminia; Michael Fay; Jennifer H Martin
Journal:  J Neurooncol       Date:  2015-02-04       Impact factor: 4.130

4.  Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.

Authors:  Elizabeth R Gerstner; Kyrre E Emblem; Ken Chang; Bella Vakulenko-Lagun; Yi-Fen Yen; Andrew L Beers; Jorg Dietrich; Scott R Plotkin; Ciprian Catana; Jacob M Hooker; Dan G Duda; Bruce Rosen; Jayashree Kalpathy-Cramer; Rakesh K Jain; Tracy Batchelor
Journal:  Clin Cancer Res       Date:  2019-09-26       Impact factor: 12.531

5.  Neuro-Oncology: Current Concepts and Emerging Therapeutics.

Authors:  Burt Nabors; John Laterra
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 6.  Practical management of bevacizumab-related toxicities in glioblastoma.

Authors:  Alba A Brandes; Marco Bartolotti; Alicia Tosoni; Rosalba Poggi; Enrico Franceschi
Journal:  Oncologist       Date:  2015-01-07

Review 7.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

8.  A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.

Authors:  Priya Kumthekar; Sean Grimm; James Chandler; Minesh Mehta; Maryanne Marymont; Robert Levy; Kenji Muro; Irene Helenowski; Katie McCarthy; Leanne Fountas; Jeffrey Raizer
Journal:  J Neurooncol       Date:  2017-05-16       Impact factor: 4.130

9.  Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

Authors:  Shiv K Gupta; Sani H Kizilbash; Brett L Carlson; Ann C Mladek; Felix Boakye-Agyeman; Katrina K Bakken; Jenny L Pokorny; Mark A Schroeder; Paul A Decker; Ling Cen; Jeanette E Eckel-Passow; Gobinda Sarkar; Karla V Ballman; Joel M Reid; Robert B Jenkins; Roeland G Verhaak; Erik P Sulman; Gaspar J Kitange; Jann N Sarkaria
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

10.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Authors:  Kathleen M Schmainda; Zheng Zhang; Melissa Prah; Bradley S Snyder; Mark R Gilbert; A Gregory Sorensen; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2015-02-02       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.